Adagene Inc.'s SEC filings document its foreign-private-issuer reporting for a clinical-stage biotechnology company developing antibody-based cancer immunotherapies. Form 6-K reports furnish clinical-data releases for muzastotug, regulatory updates for MSS colorectal cancer development, full-year financial results, business updates and notices of scientific presentations.
The filings also cover capital-structure and financing matters, including ADS offerings, underwriting agreements and the ADS-to-ordinary-share relationship. Other disclosures include licensing and collaboration agreements using SAFEbody technology, share-based compensation and equity accounts, governance updates, clinical development risks and exhibits furnished under Exchange Act reporting rules.
Adagene Inc. Executive Director of Finance Chunfang Gu had 6,250 ADSs vest on July 23, 2026; 475 ADSs were sold for tax withholding, resulting in 5,775 ADSs received. The 6,250 ADSs were equivalent to 7,813 RSUs on an ordinary share basis. As of September 30, 2026, Gu directly held 5,775 ADSs and 15,625 RSUs, granted under the 2021 Performance Incentive Plan.
Adagene Inc. Chief Financial Officer and director Tam Man Kin purchased 2,000 ADSs in the open market at $3 per ADS on September 23, 2026. His directly held ADS position was 12,000 ADSs after the purchase. A separate holding entry reports 25,000 restricted stock units directly; a footnote states they were granted under the 2021 Performance Incentive Plan in July 2024 and identifies remaining RSU vesting dates of July 23, 2027 and July 23, 2028. No Rule 10b5-1 plan is reported.
Adagene Inc. said Executive Director of Finance Chunfang (Vicky) Gu resigned for personal reasons, effective September 30, 2026. Gu confirmed she has no disagreement with the board and that there are no matters relating to her resignation that should be brought to the board’s or shareholders’ attention.
Adagene Inc. (ADAG) reports that China’s National Medical Products Administration has cleared its investigational new drug application for ADG138, a double-masked HER2×CD3 bispecific T-cell engager built on the company’s SAFEbody® precision masking technology. Adagene expects to start a first-in-human Phase 1 trial in advanced solid tumors in China in the fourth quarter of 2026.
The planned open-label Phase 1 study will assess safety, preliminary efficacy and determine a recommended Phase 2 dose. Preclinical data showed large reductions in HER2 and CD3 binding, robust tumor regression including in models refractory or resistant to Enhertu, and tolerability at doses over 300-fold higher than an unmasked T-cell engager, with reduced cytokine release.
Adagene Inc. (ADAG) reported that Chief Executive Officer and director Peter Luo purchased American Depositary Shares (ADS) of the company on September 16, 2026. He acquired 20,290 ADS in an open-market or private transaction at an average price of $3.1533 per ADS, with individual trade prices ranging from $3.00 to $3.20 per ADS. Following this purchase, he directly holds 88,535 ADS. No Rule 10b5-1 trading plan is reported for this transaction.
Adagene Inc. (ADAG) reports that partner Third Arc Bio has selected the first lead candidate under their amended strategic licensing collaboration to develop masked CD3 T cell engagers using Adagene’s NEObody® and SAFEbody® platforms. The amended terms broaden the relationship into an integrated asset and technology partnership, with Third Arc Bio sponsoring and funding clinical development of the lead program. Adagene states that total potential payments, including development and commercial milestones, have increased under the revised collaboration, and it retains a no-cost option to develop and commercialize candidate molecules in Greater China, Singapore and South Korea. The disclosure also reiterates Adagene’s focus on antibody-based cancer immunotherapies, including its lead SAFEbody program muzastotug (ADG126) in Phase 1b/2 and Phase 2 studies.
Adagene Inc. (ADAG) announced that it achieved a preclinical milestone under its collaboration and license agreement with Exelixis related to the SAFEbody-based antibody-drug conjugate candidate XB404. This milestone triggered a $2.0 million milestone payment from Exelixis to Adagene.
An additional payment was also triggered by the selection of candidates for another SAFEbody antibody-drug conjugate program. Under the collaboration, Exelixis may use Adagene’s SAFEbody technology to generate masked monoclonal antibodies, and Adagene remains eligible for further development and commercialization milestone payments and royalties on net sales of resulting products.
Adagene Inc. (ADAG) filed an amended notice under Rule 144 for planned sales of American Depositary Shares (ADSs) related to option vesting under its ESOP. An officer intends to sell ADSs each representing 1.25 ordinary shares in a sell-to-cover arrangement to satisfy costs including tax withholding arising from option vesting. The plan covers four NASDAQ transactions through Futu Securities International (Hong Kong) Ltd: 40,000 ADSs each on 08/21/2026, 08/24/2026, and 08/25/2026, and 11,000 ADSs on 08/26/2026. The filing also reports a prior sale of 475 ADSs on 07/28/2026 by Chunfang Gu.
Adagene Inc. (ADAG) is the subject of a Form 144 notice filed by officer Gu Chunfang covering proposed sales of American Depositary Shares, each representing 1.25 ordinary shares. The ADSs are to be sold through Futu Securities International (Hong Kong) Ltd on several August 2026 trade dates to cover costs, including tax withholding obligations, arising from the vesting of options granted under Adagene’s ESOP plan.
Adagene Inc. (ADAG) reported that director Do Cuong V purchased American Depositary Shares in the company. On 2026-08-14, the reporting person bought 2,000 ADS in open-market or private transactions at a price of $3.75 per ADS, resulting in direct ownership of 2,000 ADS.